Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFEGUARD: SAB-142 in Stage 3 New Onset Type 1 Diabetes
NCT07187531Phase 2Recruiting
- Sponsor
- SAB BIO
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of SAB-142 in type 1 diabetes mellitus (T1D), sponsored by SAB BIO. Started Nov 2025; status: recruiting.
02
Drugs
SAB-142
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07187531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187531.